Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/BioStem Technologies, Inc./ EFFECT

Notice of Effectiveness · EFFECT

BioStem Technologies, Inc.

Notice of Effectiveness

Filed Sep 29, 2026Accepted Sep 30, 2026, 12:15 AM EDTFiling CIK 1658678Accession 9999999995-26-003103
View company →Permanent SEC source ↗
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-09-29
Effective time (as filed)
16:00:00
Form
S-1

Registrant 1

Registrant
BioStem Technologies, Inc.
Registrant CIK
0001658678
File number
333-299025

Company context

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

Current securities

BSEMNASDAQ · EQUITY · Current
Historical securities (5)
BSEMNASDAQ · EQUITY · Historical · closed Oct 19, 2026BSEMOTC · EQUITY · Historical · closed Jan 27, 2015BSEMOTC · EQUITY · Historical · closed Jan 27, 2015BSEMDOTC · EQUITY · Historical · closed Feb 23, 2015CIHNOTC · EQUITY · Historical · closed Dec 9, 2014

Recent company filings

  1. SCHEDULE 13G - filed by PNC FINANCIAL SERVICES GROUP, INC. regarding BioStem Technologies, Inc.Nov 5, 2026
  2. 424B3 filingOct 13, 2026
  3. EFFECT filingOct 9, 2026
  4. 4 filingOct 9, 2026
  5. D filingOct 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.